Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 300 versus VISIPAQUE 270.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 300 versus VISIPAQUE 270.
OMNIPAQUE 300 vs VISIPAQUE 270
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing vascular and tissue opacification by increasing the density of blood vessels and organs.
Iodinated radiocontrast agent; attenuates X-rays, providing vascular and tissue opacification.
Intravenous: 1-2 mL/kg (300 mg I/mL) for contrast-enhanced CT; intra-arterial: 5-80 mL per injection depending on procedure; maximum total dose 4 mL/kg.
Intraarterial or intravenous administration; dose depends on procedure, age, weight, cardiac output, and clinical condition. Typical adult dose: 50-150 mL of 270 mg I/mL (50-80 mL for coronary arteriography, 30-50 mL for left ventriculography; up to 250 mL total for multiple injections).
None Documented
None Documented
The terminal elimination half-life of iohexol in patients with normal renal function (creatinine clearance > 90 mL/min) is approximately 1.5 to 2 hours. In patients with renal impairment, the half-life is significantly prolonged (up to 30 hours or more in severe renal failure), necessitating dose adjustment and careful monitoring.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment, correlating with degree of kidney dysfunction.
Omnipaque 300 (iohexol) is primarily eliminated unchanged by the kidneys via glomerular filtration. Renal excretion accounts for >95% of the administered dose within 24 hours in patients with normal renal function. Fecal excretion is negligible (<1%). Billiary excretion is minimal, with less than 0.1% recovered in bile or feces.
Renal excretion via glomerular filtration; >95% of administered dose eliminated unchanged in urine within 24 hours. Minimal biliary or fecal excretion (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent